Kezar Life Sciences (KZR) Competitors $4.05 -0.22 (-5.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.04 -0.01 (-0.37%) As of 08/1/2025 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. BHST, HURA, ALTS, CNTB, FTLF, SKYE, CHRS, PLX, CRDL, and SAVAShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include BioHarvest Sciences (BHST), TuHURA Biosciences (HURA), ALT5 Sigma (ALTS), Connect Biopharma (CNTB), FitLife Brands (FTLF), Skye Bioscience (SKYE), Coherus Oncology (CHRS), Protalix BioTherapeutics (PLX), Cardiol Therapeutics (CRDL), and Cassava Sciences (SAVA). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors BioHarvest Sciences TuHURA Biosciences ALT5 Sigma Connect Biopharma FitLife Brands Skye Bioscience Coherus Oncology Protalix BioTherapeutics Cardiol Therapeutics Cassava Sciences Kezar Life Sciences (NASDAQ:KZR) and BioHarvest Sciences (NASDAQ:BHST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk. Which has higher valuation & earnings, KZR or BHST? BioHarvest Sciences has higher revenue and earnings than Kezar Life Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.23-$83.74M-$10.82-0.37BioHarvest Sciences$27.70M4.56-$12.91M-$0.50-15.38 Is KZR or BHST more profitable? Kezar Life Sciences has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -31.30%. Kezar Life Sciences' return on equity of -61.15% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -61.15% -50.27% BioHarvest Sciences -31.30%-307.04%-33.21% Which has more risk and volatility, KZR or BHST? Kezar Life Sciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Does the media favor KZR or BHST? In the previous week, Kezar Life Sciences had 1 more articles in the media than BioHarvest Sciences. MarketBeat recorded 1 mentions for Kezar Life Sciences and 0 mentions for BioHarvest Sciences. BioHarvest Sciences' average media sentiment score of 0.00 beat Kezar Life Sciences' score of -1.00 indicating that BioHarvest Sciences is being referred to more favorably in the news media. Company Overall Sentiment Kezar Life Sciences Negative BioHarvest Sciences Neutral Do analysts rate KZR or BHST? Kezar Life Sciences currently has a consensus target price of $39.50, indicating a potential upside of 875.31%. BioHarvest Sciences has a consensus target price of $13.67, indicating a potential upside of 77.72%. Given Kezar Life Sciences' higher probable upside, research analysts plainly believe Kezar Life Sciences is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in KZR or BHST? 67.9% of Kezar Life Sciences shares are held by institutional investors. 10.4% of Kezar Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryBioHarvest Sciences beats Kezar Life Sciences on 8 of the 15 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.20M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.3717.6228.7823.81Price / Sales4.23179.21372.2066.04Price / CashN/A41.9535.4557.96Price / Book0.258.508.275.54Net Income-$83.74M-$55.06M$3.25B$259.28M7 Day Performance-6.03%-3.99%-3.70%-4.64%1 Month Performance-9.80%9.58%4.34%4.41%1 Year Performance-33.78%6.70%25.90%17.95% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences3.6576 of 5 stars$4.05-5.2%$39.50+875.3%-36.1%$31.20M$7M-0.3760Negative NewsAnalyst DowngradeShort Interest ↑BHSTBioHarvest SciencesN/A$7.50-1.1%$13.67+82.2%N/A$124.50M$25.19M-15.00N/AHURATuHURA Biosciences1.2939 of 5 stars$2.78-2.5%$12.67+355.6%N/A$124.49MN/A0.00N/AGap DownALTSALT5 SigmaN/A$6.98-1.4%N/A+302.6%$123.58M$12.53M0.00170CNTBConnect Biopharma2.6328 of 5 stars$2.08-6.3%$7.00+236.5%+73.9%$123.35M$26.03M0.00110Short Interest ↑FTLFFitLife Brands3.5497 of 5 stars$12.83-0.5%$20.50+59.8%-22.0%$121.15M$63.86M15.2720News CoverageSKYESkye Bioscience1.4692 of 5 stars$3.74-4.3%$16.60+343.9%-37.8%$121.11MN/A-4.5611Gap DownCHRSCoherus Oncology3.8227 of 5 stars$1.07+2.9%$4.68+337.7%-38.6%$120.57M$266.96M-0.95330News CoverageUpcoming EarningsHigh Trading VolumePLXProtalix BioTherapeutics2.2289 of 5 stars$1.50-0.7%$15.00+900.0%+36.2%$119.41M$59.76M-11.54200News CoverageGap UpCRDLCardiol Therapeutics1.9541 of 5 stars$1.53+6.3%$8.00+422.9%-33.7%$119.02MN/A-4.5020Gap UpHigh Trading VolumeSAVACassava Sciences3.5959 of 5 stars$2.38+1.3%$54.50+2,189.9%-91.0%$113.52MN/A-1.5930 Related Companies and Tools Related Companies BHST Competitors HURA Competitors ALTS Competitors CNTB Competitors FTLF Competitors SKYE Competitors CHRS Competitors PLX Competitors CRDL Competitors SAVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZR Stock Alerts